share_log

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43

Benzinga ·  Sep 25 00:14  · Ratings

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price target from $47 to $43.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment